SLDB (Solid Biosciences Inc.) Stock Financials & Earnings | Market Cap Arena

SLDB (Solid Biosciences Inc.) Stock Financials & Earnings | Market Cap Arena

SLDBSolid Biosciences Inc.

Mkt Cap$644M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$167M

EPS (TTM)-$2.29

Free Cash Flow (TTM)-$133M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$35M
Q1 23	$0	$0	-$32M
Q2 23	$0	$0	-$27M
Q3 23	$0	$0	-$23M
Q4 23	$0	$0	-$22M
Q1 24	$0	-$327K	-$27M
Q2 24	$0	$0	-$28M
Q3 24	$0	$0	-$35M
Q4 24	$0	$0	-$40M
Q1 25	$0	-$407K	-$40M
Q2 25	$0	-$386K	-$42M
Q3 25	$0	$0	-$48M

Valuation

Quarter	P/S	P/E
Q4 22	79.5x	—
Q1 23	104.4x	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$34M	-$35M
Q1 23	-$28M	-$29M
Q2 23	-$27M	-$28M
Q3 23	-$18M	-$18M
Q4 23	-$21M	-$21M
Q1 24	-$25M	-$25M
Q2 24	-$21M	-$22M
Q3 24	-$24M	-$24M
Q4 24	-$30M	-$30M
Q1 25	-$32M	-$32M
Q2 25	-$37M	-$38M
Q3 25	-$33M	-$34M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$856K
Q1 23	$506K
Q2 23	$536K
Q3 23	$383K
Q4 23	$90K
Q1 24	$149K
Q2 24	$286K
Q3 24	$15K
Q4 24	$204K
Q1 25	$126K
Q2 25	$377K
Q3 25	$85K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-100.0%	+58.5%
Q1 23	-100.0%	+17.3%
Q2 23	-100.0%	-14.9%
Q3 23	—	+9.4%
Q4 23	—	-35.6%
Q1 24	—	-16.1%
Q2 24	—	+3.5%
Q3 24	—	+52.2%
Q4 24	—	+79.2%
Q1 25	—	+49.1%
Q2 25	—	+50.0%
Q3 25	—	+36.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$2M	—
Q1 23	$2M	—
Q2 23	$2M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$2M	—
Q2 24	$2M	—
Q3 24	$3M	—
Q4 24	$4M	—
Q1 25	$3M	—
Q2 25	$3M	—
Q3 25	$4M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 22	$21M	$8M
Q1 23	$25M	$7M
Q2 23	$20M	$7M
Q3 23	$17M	$6M
Q4 23	$15M	$7M
Q1 24	$19M	$8M
Q2 24	$19M	$8M
Q3 24	$27M	$8M
Q4 24	$31M	$9M
Q1 25	$31M	$9M
Q2 25	$32M	$9M
Q3 25	$39M	$9M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$155M	$58M	$214M
Q1 23	$165M	$21M	$186M
Q2 23	$92M	$69M	$160M
Q3 23	$49M	$94M	$143M
Q4 23	$74M	$50M	$124M
Q1 24	$118M	$88M	$206M
Q2 24	$96M	$94M	$190M
Q3 24	$64M	$107M	$171M
Q4 24	$80M	$69M	$149M
Q1 25	$211M	$96M	$307M
Q2 25	$139M	$129M	$268M
Q3 25	$61M	$175M	$236M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	8M	+6.5%
Q1 23	20M	+143.9%
Q2 23	20M	+0.5%
Q3 23	20M	+2.0%
Q4 23	29M	+44.7%
Q1 24	38M	+31.5%
Q2 24	41M	+7.3%
Q3 24	41M	+1.2%
Q4 24	54M	+29.3%
Q1 25	66M	+23.8%
Q2 25	94M	+41.9%
Q3 25	94M	+0.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 15	—	—
FY 16	—	—
FY 17	$0	60
FY 18	$0	111
FY 19	$0	121
FY 20	$0	70
FY 21	$131K	104
FY 22	$93K	87
FY 23	$0	88
FY 24	$0	100